Initiation of therapy during primary HIV type 1 infection results in a continuous decay of proviral DNA and a highly restricted viral evolution

AIDS Research and Human Retroviruses

Volumn 17, Issue 5, 2001, Pages 409-416

  Karlsson, A C ^a   Birk, M ^a   Lindback S ^a   Gaines, H ^b   Mittler, J E ^c   Sonnerborg A ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; VIRUS DNA;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; DRUG POTENCY; HALF LIFE TIME; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MEMORY CELL; MOLECULAR CLONING; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; TREATMENT OUTCOME; VIREMIA; VIROGENESIS; VIRUS LOAD; VIRUS REPLICATION;

DNA, VIRAL; EVOLUTION, MOLECULAR; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; MOLECULAR SEQUENCE DATA; PROVIRUSES; REVERSE TRANSCRIPTASE INHIBITORS; SEQUENCE ANALYSIS; TIME FACTORS; VIRUS REPLICATION;

EID: 0035794307     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922201750102463     Document Type: Article

References (37)

1. In vivo fate of HIV-1-infected T cells: Quantitative analysis of the transition to stable latency
2. Early establishment of a pool of latently infected, resting CD41 T cells during primary HIV-1 infection
3. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy
4. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy
5. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy
6. Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy
7. The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy
8. Latent infection of CD41 T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy
9. Highly active antiretroviral treatment initiated early in the course of symptomatic primary HIV-1 infection: Results of the ANRS 053 trial
10. Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy
11. Evolution of envelope sequences of human immunodeficiency virus type 1 in cellular reservoirs in the setting of potent antiviral therapy
12. Characterization of the viral population during primary HIV-1 infection
13. Reappearance of founder virus sequence in human immunodeficiency virus type 1-infected patients
14. Viral dynamics in primary HIV-1 infection
15. Quantification of HIV-1 proviral DNA from peripheral blood mononuclear cells using a high throughput four-competitor competitive PCR
16. Human immunodeficiency virus-infected individuals contain provirus in small numbers of peripheral mononuclear cells and at low copy numbers
17. HIV quasispecies and resampling
18. Long terminal repeat promoter/enhancer activity of different subtypes of HIV-1
19. Tempo and mode of nucleotide substitutions in gag and env gene fragments in human immunodeficiency virus type 1 populations with a known transmission history
20. Reconstructing evolution from eukaryotic small-ribosomal-subunit RNA sequences: Calibration of the molecular clock
21. Reverse transcriptase and substrate dependence of the RNA hypermutagenesis reaction
22. Selection, recombination, and G → A hypermutation of human immunodeficiency virus type 1 genomes
23. Erratic G → A hypermutation within a complete caprine arthritis-encephalitis virus (CAEV) provirus
24. Does symptomatic primary HIV-1 infection accelerate progression to CDC stage IV disease, CD4 count below 200 × 10(6)/1, AIDS, and death from AIDS?
25. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy
26. Proviral HIV-1 V3 sequence variation in patients receiving efficient long-term antiretroviral combination therapy
27. Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection
28. Lifespan of human lymphocyte subsets defined by CD45 isoforms
29. Treatment of human immunodeficiency virus infection with hydroxyurea, didanosine, and a protease inhibitor before seroconversion is associated with normalized immune parameters and limited viral reservoir
30. Selection for specific sequences in the external envelope protein of human immunodeficiency virus type 1 upon primary infection
31. Genotypic and phenotypic characterization of HIV-1 patients with primary infection
32. Host-specific driving force in human immunodeficiency virus type 1 evolution in vivo
33. Adaptive evolution of human immunodeficiency virus-type 1 during the natural course of infection
34. Evolution of sequences encoding the principal neutralization epitope of human immunodeficiency virus 1 is host dependent, rapid, and continuous
35. Slower evolution of human immunode-ficiency virus type-1 quasispecies during progression to AIDS
36. Effect of immune activation on the dynamics of human immunodeficiency virus replication and on the distribution of viral quasispecies